Regen BioPharma (RGBP) 10-K 22 Dec 21 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Sep. 30, 2021	Dec. 21, 2021	Dec. 06, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--09-30
Entity File Number	333-191725
Entity Registrant Name	REGEN BIOPHARMA, INC
Entity Central Index Key	0001589150
Entity Tax Identification Number	45-5192997
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	Suite 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	619
Local Phone Number	722 5505
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float		$ 7,330,721
Entity Common Stock, Shares Outstanding			4,564,002,832

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Sep. 30, 2020
CURRENT ASSETS
Cash	$ 727,162
Accounts Receivable, Related Party	213,192	103,192
Note Receivable, Related Party	5,396	0
Accrued Interest Receivable	230	0
Prepaid Expenses	48,144	28
Total Current Assets	994,124	103,220
OTHER ASSETS
Investment Securities	198,006	0
Investment Securities, Related Party	19,969	19,969
Total Other Assets	217,975	19,969
TOTAL ASSETS	1,212,099	123,189
Current Liabilities:
Accounts payable	91,498	110,486
Notes Payable	1,429,179	62,127
Accrued payroll taxes	4,241	4,241
Accrued Interest	954,861	830,061
Accrued Rent	0	23,548
Accrued Payroll	1,266,679	1,189,319
Other Accrued Expenses	41,423	41,423
Bank Overdraft	1,000	1,000
Due to Investor	20,000	20,000
Unearned Income	1,843,806
Derivative Liability	6,892,477	2,634,215
Convertible Notes Payable Less unamortized discount	2,131,311	2,522,716
Convertible Notes Payable, Related Parties Less unamortized discount	21,500	19,050
Total Current Liabilities	14,697,976	7,458,187
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount	0	0
Total Liabilities	14,697,976	7,458,187
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 4,800,000,000 authorized and 1,605,000,246 issued and outstanding as of September 30, 2020 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding September 30,2021.	435,054	160,498
Additional Paid in capital	8,644,037	8,313,877
Contributed Capital	736,326	731,711
Retained Earnings (Deficit)	(23,348,900)	(16,583,666)
Total Stockholders' Equity (Deficit)	(13,485,877)	(7,334,998)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	1,212,099	123,189
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	43,200	38,177
Series AA Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	5	5
Series M Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	4,400	4,400
Series N C [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, Value, Issued	$ 1	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	4,800,000,000	4,800,000,000
Common stock, shares issued	4,350,554,514	1,605,000,246
Common stock, shares outstanding	4,350,554,514	1,605,000,246
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	381,768,689	431,998,817
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	50,000	50,000
Series M Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares outstanding	44,000,000	44,000,000
Series N C [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	0
Preferred stock, shares outstanding	10,000	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
RE VENUES
Revenues	$ 61,194
Revenues, Related Party	110,000	110,000
TOTAL REVENUES	171,194	110,000
COST AND EXPENSES
Research and Development	36,704	13,286
General and Administrative	119,495	249,697
Consulting and Professional Fees	190,765	37,786
Rent	25,000	18,548
Total Costs and Expenses	371,965	319,317
OPERATING INCOME (LOSS)	(200,771)	(209,317)
OTHER INCOME & (EXPENSES)
Interest Income	230	0
Interest Expense	(316,013)	(333,411)
Interest Expense attributable to Amortization of Discount	(51,015)	(609,522)
Gain( Loss) on sale of Investment Securities	(524,960)	0
Unrealized Gain ( Loss) on sale of Investment Securities	(632,094)	0
Derivative Income (Expense)	(4,264,975)	4,566,669
Gain (Loss) on Early Extinguishment Convertible Debt	24,365	0
Legal Settlement	(800,000)	0
TOTAL OTHER INCOME (EXPENSE)	(6,564,462)	3,623,736
NET INCOME (LOSS)	(6,765,233)	3,414,419
NET INCOME (LOSS) attributable to common shareholders	$ (6,765,233)	$ 2,731,535
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.00225)	$ 0.002
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	3,011,544,584	1,409,846,576

Consolidated Statement of Share

Consolidated Statement of Shareholder's Deficit - USD ($)	Preferred Stock Series A [Member]	Series AA Preferred Stock	Series N C Preferred Stock [Member]	Common Stock [Member]	Series M Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Sep. 30, 2019	$ 34,838	$ 5		$ 59,998	$ 3,800	$ 8,261,993	$ (19,998,086)	$ 728,658			$ (10,908,795)
Beginning balance, Shares at Sep. 30, 2019	348,376,230	50,000		600,001,406	38,000,000
Shares issued for Debt				$ 1,510		3,397					4,907
Shares issued for Debt, Shares				15,100,608
Shares issued for Interest				$ 438		984					1,422
Shares Issued For Interest, Shares				4,376,007
Shares issued for Debt				$ 2,083		7,917					10,000
Shares issued for Debt, Shares				20,834,497
Shares issued for Interest				$ 342		1,299					1,641
Shares Issued For Interest, Shares				3,418,941
Shares issued for Debt				$ 2,500		6,500					9,000
Shares issued for Debt, Shares				25,002,163
Shares issued for Interest				$ 422		1,096					1,518
Shares Issued For Interest, Shares				4,217,031
Shares issued for Debt				$ 1,925		3,850					5,775
Shares issued for Debt, Shares				19,254,584
Shares issued for Interest				$ 875		1,750					2,625
Shares issued for Interest, Shares				8,745,416
Shares issued for Debt				$ 3,056		7,944					11,000
Shares issued for Debt, Shares				30,555,555
Shares issued for Services					$ 600						600
Shares issued for services, Shares					6,000,000
Shares issued for Interest				$ 3,095		(310)					2,785
Shares issued for Interest, Shares				30,946,444
Shares issued for Debt				$ 3,650		2,920					6,570
Shares Issued for Debt, Shares				36,500,000
Shares issued for Debt				$ 3,125		3,625					6,750
Shares Issued for Debt, Shares				31,251,177
Shares issued for Interest				$ 439		510					949
Shares issued for Interest, Shares				4,393,684
Shares issued for Debt				$ 3,056		2,444					5,500
Shares Issued for Debt, Shares				30,558,094
Shares issued for interest				$ 556		444					1,000
Shares issued for Interest, Shares				5,556,017
Shares issued for Debt				$ 3,123		2,967					6,090
Shares Issued for Debt, Shares				31,234,276
Shares issued for interest				$ 531		504					1,035
Shares issued for Interest, Shares				5,308,288
Shares issued for Debt				$ 4,192		3,354					7,546
Shares Issued for Debt, Shares				41,922,222
Shares issued for Debt				$ 1,006		(99)					907
Shares Issued for Debt, Shares				10,064,761
Shares issued for interest				$ 2,631		(260)					2,371
Shares issued for Interest, Shares				26,310,416
Shares issued for Fees				$ 555		(55)					500
Shares issued for Fees, Shares				5,548,380
Shares issued for Debt				$ 4,973		905					5,878
Shares Issued for Debt, Shares				49,729,272
Shares Issued for Debt				$ 3,778		(1,512)					2,266
Shares Issued for Debt, Shares				37,777,157
Shares issued for interest				$ 610		(244)					366
Shares issued for Interest, Shares				6,101,694
Shares issued for Fees				$ 834		(334)					500
Shares issued for Fees, Shares				8,335,648
Shares Issued for Debt				$ 5,220		(2,088)					3,132
Shares Issued for Debt, Shares				52,200,000
Shares Issued for Debt				$ 4,208		1,262					5,470
Shares Issued for Debt, Shares				42,081,411
Shares issued for interest				$ 768		230					998
Shares issued for Interest, Shares				7,677,742
Shares Issued for Debt				$ 4,143		3,314					7,457
Shares Issued for Debt, Shares				41,433,258
Shares issued for Interest				$ 57		45					102
Shares issued for Interest, Shares				566,742
Shares Issued for Debt				$ 5,046		(1,766)					3,280
Shares Issued for Debt, Shares				50,462,834
Shares issued for Interest				$ 948		(332)					616
Shares issued for Interest, Shares				9,477,166
Shares issued for Debt				$ 5,990		(2,396)					3,594
Shares issued for Debt, Shares				59,900,000
Shares issued for Debt				$ 3,142		(2,200)					942
Shares issued for Debt, Shares				31,421,505
Shares issued for Interest				$ 1,181		(827)					354
Shares issued for Interest, Shares				11,808,081
Shares issued for Fees				$ 1,668		(1,168)					500
Shares issued for Fees, Shares				16,678,081
Capital Contribution Quarter ended September 30,2020								133			133
Net Loss							3,082,768				3,083,375
Ending balance, value at Dec. 31, 2019	$ 34,838	$ 5		$ 142,228	$ 4,400	8,305,609	(16,915,318)	728,791			(7,699,447)
Ending balance, Shares at Dec. 31, 2019	348,376,230	50,000		1,422,306,114	44,000,000
Shares issued for Debt				$ 6,969		(3,206)					3,763
Shares issued for Debt, Shares				69,685,185
Shares issued for Interest				$ 1,748		(1,224)					524
Shares Issued For Interest, Shares				17,480,000
Shares issued for Debt				$ 3,683		(2,578)					1,105
Shares issued for Debt, Shares				36,826,333
Shares issued for Interest				$ 1,862		(1,304)					558
Shares Issued For Interest, Shares				18,615,919
Shares issued for Debt				$ 674		(472)					202
Shares issued for Debt, Shares				6,739,096
Shares issued for Fees				$ 1,667		(1,167)					500
Shares issued for Fees, Shares				16,666,667
Shares issued for Fees				$ 1,668		(1,168)					500
Shares issued for Fees, Shares				16,680,931
Net Loss							(4,077,145)				(4,077,145)
Ending balance, value at Mar. 31, 2020	$ 34,838	$ 5		$ 160,498	$ 4,400	8,294,491	(20,992,464)	728,791			(11,769,440)
Ending balance, Shares at Mar. 31, 2020	348,376,230	50,000		1,605,000,246	44,000,000
Net Loss							3,205,944				3,205,944
Preferred Shares issued for Debt	$ 356					2,645					3,000
Preferred Shares issued for Debt, Shares	3,550,977.18
Preferred Shares issued for Interest	$ 169					1,257					1,426
Preferred Shares issued for Interest, Shares	1,687,897.82
Ending balance, value at Jun. 30, 2020	$ 35,362	$ 5		$ 160,498	$ 4,400	8,298,393	(17,786,519)	728,791			(8,559,070)
Ending balance, Shares at Jun. 30, 2020	353,615,105	50,000		1,605,000,246	44,000,000
Capital Contribution Quarter ended September 30,2020								2,920			2,920
Net Loss							1,202,853				1,202,853
Preferred Shares issued for Debt	$ 769					4,231					5,000
Preferred Shares issued for Debt, Shares	7,692,776
Preferred Shares issued for Interest	$ 391					2,151					2,542
Preferred Shares issued for Interest, Shares	3,911,008
Preferred Shares issued for Debt	$ 1,077					5,923					7,000
Preferred Shares issued for Debt, Shares	10,769,800
Preferred Shares issued for Interest	$ 578					3,179					3,757
Preferred Shares issued for Interest, Shares	5,780,000
Ending balance, value at Sep. 30, 2020	$ 38,177	$ 5		$ 160,498	$ 4,400	8,313,876	(16,583,666)	731,711			(7,334,998)
Ending balance, Shares at Sep. 30, 2020	381,768,689	50,000		1,605,000,246	44,000,000
Shares issued for Debt				$ 5,773		(2,021)					3,752
Shares issued for Debt, Shares				57,726,183
Shares issued for Interest				$ 2,234		(782)					1,452
Shares Issued For Interest, Shares				22,339,663
Shares issued for Debt				$ 6,001		(2,101)					3,900
Shares issued for Debt, Shares				60,007,919
Shares issued for Interest				$ 2,393		(838)					1,555
Shares Issued For Interest, Shares				23,926,234
Shares issued for Debt				$ 6,083		1,217					7,300
Shares issued for Debt, Shares				60,834,498
Shares issued for Interest				$ 2,619		523					3,142
Shares Issued For Interest, Shares				26,185,501
Shares issued for Debt				$ 330		99					429
Shares issued for Debt, Shares				3,300,000
Shares issued for Interest				$ 182		54					236
Shares issued for Interest, Shares				1,819,077
Shares issued for Debt				$ 6,200		(2,170)					4,030
Shares issued for Debt, Shares				62,003,571
Shares issued for Interest				$ 2,616		(916)					1,700
Shares issued for Interest, Shares				26,155,352
Shares issued for Debt				$ 6,833		1,367					8,200
Shares Issued for Debt, Shares				68,333,539
Shares issued for Debt	$ 2,000					11,000					13,000
Shares Issued for Debt, Shares	20,000,437
Shares issued for Interest				$ 1,488		212					1,700
Shares issued for Interest, Shares				14,883,378
Shares issued for Debt				$ 8,889		7,111					16,000
Shares Issued for Debt, Shares				88,888,889
Shares issued for interest	$ 1,238					6,808					8,046
Shares issued for Interest, Shares	12,378,732
Shares issued for Debt				$ 8,200		(2,870)					5,330
Shares Issued for Debt, Shares				82,004,603
Shares issued for interest				$ 1,956		1,294					3,250
Shares issued for Interest, Shares				19,555,555
Shares issued for interest				$ 3,583		(1,254)					2,329
Shares issued for Interest, Shares				35,832,781
Shares issued for Fees				$ 123		36					159
Shares issued for Fees, Shares				1,228,077
Net Loss							1,666,367				1,666,367
Additions to Contributed Capital Quarter ended 3/31/2021								1,865			1,865
Ending balance, value at Dec. 31, 2020	$ 41,415	$ 5		$ 226,001	$ 4,400	8,330,646	(14,917,299)	733,576			(5,581,256)
Ending balance, Shares at Dec. 31, 2020	414,147,858	50,000		2,260,025,066	44,000,000
Shares issued for Debt				$ 8,590		(3,436)					5,154
Shares issued for Debt, Shares				85,900,000
Shares issued for Interest				$ 8,800		(4,400)					4,400
Shares Issued For Interest, Shares				88,000,000
Shares issued for Debt				$ 7,143		22,857					30,000
Shares issued for Debt, Shares				71,430,421
Shares issued for Interest				$ 1,133		3,625					4,758
Shares Issued For Interest, Shares				11,328,865
Shares issued for Debt				$ 8,093		(2,833)					5,260
Shares issued for Debt, Shares				80,928,505
Shares issued for Interest				$ 3,834		(1,342)					2,492
Shares Issued For Interest, Shares				38,341,033
Shares issued for Debt				$ 6,718		(3,361)					3,357
Shares issued for Debt, Shares				67,175,355
Shares issued for Interest				$ 882		(441)					441
Shares issued for Interest, Shares				8,824,645
Shares issued for Debt				$ 1,667		(667)					1,000
Shares issued for Debt, Shares				16,666,667
Shares issued for Interest				$ 9,583		(3,833)					5,750
Shares issued for Interest, Shares				95,833,333
Shares issued for Debt				$ 6,832		(3,417)					3,415
Shares Issued for Debt, Shares				68,319,520
Shares issued for Debt				$ 3,852		(1,927)					1,925
Shares Issued for Debt, Shares				38,519,260
Shares issued for Interest				$ 168		(84)					84
Shares issued for Interest, Shares				1,680,480
Shares issued for interest				$ 148		(74)					74
Shares issued for Interest, Shares				1,480,740
Net Loss							442,183				442,183
Additions to Contributed Capital Quarter ended 3/31/2021								250			250
Ending balance, value at Mar. 31, 2021	$ 41,415	$ 5	$ 0	$ 293,444	$ 4,400	8,331,313	(14,475,117)	733,826			(5,070,713)
Ending balance, Shares at Mar. 31, 2021	414,147,858	50,000	0	2,934,453,890	44,000,000
Shares issued for Debt				$ 8,421		(5,310)					3,111
Shares issued for Debt, Shares				84,214,968
Shares issued for Interest				$ 79		(30)					49
Shares Issued For Interest, Shares				785,032
Shares issued for Debt				$ 2,639		16,361					19,000
Shares issued for Debt, Shares				26,389,990
Shares issued for Interest				$ 658		4,078					4,736
Shares Issued For Interest, Shares				6,578,052
Shares issued for Debt				$ 5,850		(2,340)					3,510
Shares issued for Debt, Shares				58,502,448
Shares issued for Interest				$ 2,513		(1,005)					1,508
Shares Issued For Interest, Shares				25,134,385
Shares issued for Debt				$ 9,754		(3,414)					6,340
Shares issued for Debt, Shares				97,542,355
Shares issued for Interest				$ 4,891		(1,712)					3,179
Shares issued for Interest, Shares				48,909,645
Shares issued for Debt				$ 3,815		(1,527)					2,288
Shares issued for Debt, Shares				38,145,154
Shares issued for Interest				$ 1,134		(454)					680
Shares issued for Interest, Shares				11,336,846
Shares issued for Debt				$ 8,995		(4,757)					4,238
Shares Issued for Debt, Shares				89,950,579
Shares issued for Debt				$ 6,026		40,974					47,000
Shares Issued for Debt, Shares				60,257,055
Shares issued for Interest				$ 36		(19)					17
Shares issued for Interest, Shares				360,821
Shares issued for Debt				$ 12,642		(4,987)					7,655
Shares Issued for Debt, Shares				126,423,649
Shares issued for interest				$ 1,050		7,139					8,189
Shares issued for Interest, Shares				10,498,830
Shares issued for Debt				$ 2,445		19,555					22,000
Shares Issued for Debt, Shares				24,445,152
Shares issued for interest				$ 3,739		(1,475)					2,264
Shares issued for Interest, Shares				37,390,351
Shares issued for Debt				$ 2,179		(763)					1,416
Shares Issued for Debt, Shares				21,792,903
Shares issued for Debt				$ 1,827		(640)					1,187
Shares Issued for Debt, Shares				18,271,120
Shares issued for interest				$ 434		3,471					3,905
Shares issued for Interest, Shares				4,339,015
Shares issued for Debt				$ 3,377		(1,351)					2,026
Shares Issued for Debt, Shares				33,772,000
Shares issued for interest				$ 1,122		(393)					729
Shares issued for Interest, Shares				11,219,652
Shares issued for interest				$ 948		(332)					616
Shares issued for Interest, Shares				9,481,896
Net Loss							(7,489,115)				(7,489,115)
Preferred Shares issued for Services			$ 1								1
Preferred Shares issued for Services, Shares			10,000
Contributed Capital Quarter Ended June 30, 2021								2,500			2,500
Ending balance, value at Jun. 30, 2021	$ 41,415	$ 5	$ 1	$ 378,018	$ 4,400	8,392,382	(21,964,232)	736,326			(12,411,685)
Ending balance, Shares at Jun. 30, 2021	414,147,858	50,000	10,000	3,780,195,788	44,000,000
Shares issued for Debt				$ 500							500
Shares issued for Debt, Shares				4,999,975
Shares issued for Interest				$ 19,344							19,344
Shares Issued For Interest, Shares				193,439,025
Shares issued for Debt				$ 10,000							10,000
Shares issued for Debt, Shares				100,000,000
Shares issued for Interest				$ 10,000							10,000
Shares Issued For Interest, Shares				100,000,000
Shares issued for Debt				$ 10,000							10,000
Shares issued for Debt, Shares				100,000,000
Shares issued for Interest				$ 52		12,941					12,993
Shares Issued For Interest, Shares				519,722
Shares issued for Debt				$ 140		34,860					35,000
Shares issued for Debt, Shares				1,400,004
Shares issued for Interest	$ 199					24,677					24,876
Shares issued for Interest, Shares	1,990,099
Shares issued for Debt				$ 7,000		(2,800)					4,200
Shares issued for Debt, Shares				70,000,000
Shares issued for Interest	$ 198					24,582					24,780
Shares issued for Interest, Shares	1,982,422
Shares issued for Debt	$ 400					49,600					50,000
Shares Issued for Debt, Shares	4,000,038
Shares issued for Debt	$ 400					49,600					50,000
Shares Issued for Debt, Shares	4,000,044
Shares issued for Interest	$ 188					18,595					18,783
Shares issued for Interest, Shares	1,878,318
Shares issued for Debt	$ 400					39,600					40,000
Shares Issued for Debt, Shares	4,000,038
Net Loss							(1,384,668)				(1,384,668)
Ending balance, value at Sep. 30, 2021	$ 43,200	$ 5	$ 1	$ 435,054	$ 4,400	$ 8,644,037	$ (23,348,900)	$ 736,326			$ (13,485,877)
Ending balance, Shares at Sep. 30, 2021	431,998,817	50,000	10,000	4,350,554,514	44,000,000

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATI.NG ACTIVITIES
Net Income (loss)	$ (6,765,233)	$ 3,414,419
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants		600
Common Stock issued for Expenses	159	3,000
Preferred Stock issued as compensation	1
Increase (Decrease) in Interest expense attributable to amortization of Discount	51,015	609,522
Increase (Decrease) in Accounts Payable	(18,988)	18,487
(Increase) Decrease in Accounts Receivable	(109,999)	(34,100)
Increase (Decrease) in accrued Expenses	369,825	569,285
(Increase) Decrease in Prepaid Expenses	(48,146)	48
Increase(Decrease) in Contributed Capital	4,615	3,053
Increase in Derivative Expense	4,264,974	(4,566,669)
Increase in Unearned Income	1,843,806
Increase (Decrease) in Bank Overdraft		1,000
(Increase( Decrease in Notes Receivable	(5,396)
(Increase( Decrease in Accrued Interest Receivable	(230)
Securities accepted as compensation	(1,850,000)
Increase (Decrease) in Loss on Sale of Investment Securities	524,930
(Gain) Loss on Forgiveness of Debt	(24,364)
Unrealized Loss(Gain) on Investment Securities	632,094
Net Cash Provided by (Used in) Operating Activities	(1,130,938)	18,645
Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities	495,000
Net Cash Provided By Investment Activities	495,000
CASH FLOWS FROM FINANCING ACTIVITIES
Increase ( Decrease) in Notes Payable	1,363,100	(26,500)
Net Cash Provided by (Used in) Financing Activities	1,363,100	(26,500)
Net Increase (Decrease) in Cash	727,162	(7,855)
Cash at Beginning of Period		7,855
Cash at End of Period	727,162
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	278,423	111,133
Preferred Shares Issued for Debt	153,000	15,000
Cash Paid for Interest		0
Common shares Issued for Interest	101,929	18,864
Preferred Shares issued for Interest	$ 76,485	$ 7,725

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of September 30, 2021 utilized the following inputs: Schedule of Derivative Liability Schedule of Derivative Liability Risk Free Interest Rate 1.49 % Expected Term ( 3.07 1.09 Expected Volatility 824.95 % Expected Dividends H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100 Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $ 0 K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. As of September 30,2021 the Company has the following Notes Receivable Schedule of notes receivable Zander Therapeutics, Inc. $ 5,396 $5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Sep. 30, 2021
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 23,348,900 Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 4. NOTES PAYABLE (a) RELATED PARTY Notes Payable Related Party Notes Payable Related Party As of September 30, 2021 David Koos $ 227 Total: $ 227 $ 227 15 (b) NON RELATED PARTY Non Related Party Coventry Enterprises LLC, $ 1,500,000 Total: $ 1,500,000 On September 17,2021 the “Company” issued a promissory note in the principal amount of $ 1,500,000 75,000 35,000 1,390,000 The Note carries “Guaranteed Interest” on the principal amount at the rate of 5 62,500 The Principal Amount and the Guaranteed Interest shall be due and payable in five equal monthly payments of $ 312,500 Solely following an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder. The conversion price of the Note is 90% of the lowest per-share Trading Price per share. Trading Price is defined as the lowest daily VWAP for the 20 Trading Days preceding a Conversion Date. VWAP is defined as the dollar volume-weighted average price for the common shares as reported by Bloomberg. The OID is being amortized by the Company over the term of the Note. As of September 30,2021 the unamortized discount on this Note is $ 71,048

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
	Sep. 30, 2021
Convertible Notes Payable
CONVERTIBLE NOTES PAYABLE	NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 100,000 100,000 8 The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $ 42,600 0 100,000 On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 8 The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $ 9,900 0 50,000 On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $ 50,000 0 50,000 On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $ 50,000 0 50,000 On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per shae. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $ 50,000 0 50,000 On March 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 75,000 75,000 10 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30 , 2021 $ 75,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 296,052 The issuance of the Note amounted in a discount of $ 75,000 0 On March 9, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 25,000 25,000 10 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30,2021 $ 25,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 98,684 25,000 0 March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30,2021 $ 50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 197,368 50,000 0 On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30,2021 $ 50,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 197,368 50,000 0 On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 25,000 25,000 10 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30,2021 $ 25,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 98,684 25,000 0 On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of September 30,2021 $ 50,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 197,368 50,000 0 On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 200,000 200,000 10 (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iii) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of September 30,2021 $ 200,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 789,474 200,000 0 On May 10, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 100,000 100,000 10 (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iii) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of September 30,2021 $ 100,000 The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $ 394,737 100,000 0 On May 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 50,000 10 (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on n

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6. RELATED PARTY TRANSACTIONS On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby: 1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement. 2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement. 3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement. No actions were taken by any of the parties to enforce the terms of the Agreement. On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be: a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto. Zander and Regen are under common control. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $ 350,000 10 Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of September 30, 2021, $ 10,000 During the quarter ended June 30, 2021 Zander Therapeutics, Inc. issued a promissory note in the amount of $5,396 to the Company as consideration for expenses of Zander Therapeutics Inc., paid by the Company. The Note is payable on demand of the Holder and bears simple interest at 10% per annum. As of September 30, 2021 the Company is indebted to David R. Koos the Compoany’s sole officer and director in the amount of $ 227 227 During the year ended September 30, 2021 the Company paid $25,000 of rental expenses to the landlord of BST Partners as consideration to BST Partners for use of office space.

ACCOUNTS RECEIVABLE, RELATED PA

ACCOUNTS RECEIVABLE, RELATED PARTY	12 Months Ended
	Sep. 30, 2021
Credit Loss [Abstract]
ACCOUNTS RECEIVABLE, RELATED PARTY	NOTE 7. ACCOUNTS RECEIVABLE, RELATED PARTY Accounts Receivable due from Related Party as of September 30, 2021 consists solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics ( See Note 6).

INCOME TAXES

INCOME TAXES	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8. INCOME TAXES As of September 30, 2021 Deferred tax assets Deferred tax assets Deferred tax assets: Net operating tax carry forwards $ 4,903,269 Other -0- Gross deferred tax assets 4,903,269 Valuation allowance (4,903,269 ) Net deferred tax assets $ -0- As of September 30 2021 the Company has a Deferred Tax Asset of $ 4,903,269 23,348,900 Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders. As the Company will require cash infusions in order to implement its business plan, and as it is probable, although not guaranteed, that such funding needs may be met through the sale of equity securities to “5-percent shareholders”, the Company recognized a valuation allowance equal to the deferred Tax Asset and the Company recorded a valuation allowance reducing all deferred tax assets to 0.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Sep. 30, 2021
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 9. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of September 30,2021: Common stock, $ 0 .0001 4,800,000,000 4,350,554,514 With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $ 0.0001 800,000,000 600,000 50,000 300,000,000 431,998,817 300,000,000 44,000,000 20,000 10,000 The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 0.0001 Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The Board of Directors of Regen have authorized 300,000,000 0.0001 The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as "Series NC Preferred Stock"). The Board of Directors of Regen have authorized 20,000 0.0001 The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

INVESTMENT SECURITIES, RELATED

INVESTMENT SECURITIES, RELATED PARTY	12 Months Ended
	Sep. 30, 2021
Investment Securities Related Party
INVESTMENT SECURITIES, RELATED PARTY	NOTE 10. INVESTMENT SECURITIES, RELATED PARTY On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 On November 29, 2018 the Company accepted 725,000 13,124 On September 30,2021 the Company revalued 470,588 725,000 Dividend Income Dividend Income Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 74,298 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 20,274 Investment Securities 593,357 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 500,000 Accrued Expenses Related Parties 89,529 Accrued Expenses 203,037 Enterprise Value 2,826,507 Less: Total Debt ( 2,061,607 ) Portion of Enterprise Value Attributable to Shareholders 764,900 Fair Value Per Share $ 0.0167 The abovementioned constitute the Company’s sole related party investment securities as of September 30, 2021 As of September 30, 2021: Comprehensive Income 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gains Net Unrealized Gain or (Loss) realized during the Year ended September 30,2021 $ 5,741 $ 7,858 $ 2,118 $ 0 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the Year ended September 30,2021 $ 13,124 $ 12,109 $ (1,104 ) $ 0

INVESTMENT SECURITIES

INVESTMENT SECURITIES	12 Months Ended
	Sep. 30, 2021
Disclosure Investment Securities Abstract
INVESTMENT SECURITIES	NOTE 11. INVESTMENT SECURITIES During the quarter ended June 30, 2021 the Company was paid 50,000 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between KCL Therapeutics, Inc. ( a wholly owned subsidiary of the Company) and Oncology Pharma, Inc. whereby Oncology Pharma, Inc. was granted a license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. During the quarter ended June 30, 2021 13,000 300,000 During the quarter ended September 30, 2021 18,000 195,000 As of September 30, 2021 18,300 common shares of Oncology Pharma, Inc. constitute the sole investment securities other than shares of Zander Therapeutics, Inc. held by the Company. On September 30,2021 the Company revalued 18,300 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market. As of September 30, 2021: Investment Securities 18,300 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the Year ended September 30,2021 $ 677,100 $ 198,006 $ 479,094 479,094

STOCK TRANSACTIONS

STOCK TRANSACTIONS	12 Months Ended
	Sep. 30, 2021
Stock Transactions
STOCK TRANSACTIONS	NOTE 12. STOCK TRANSACTIONS Quarter ended December 31, 2020 Issuance of Common Shares: On October 28, 2020 the Company issued 80,065,846 3,752 1,452 On November 6, 2020 the Company issued 83,934,153 3,900 1,555 On December 11, 2020 the Company issued 87,020,000 7,300 3,142 On December 16, 2020 the Company issued 6,437,153 429 236 On December 16, 2020 the Company issued 88,158,923 4,030 1,700 On December 17, 2020 the Company issued 83,216,917 8,200 1,786 On December 23, 2020 the Company issued 108,444,444 16,000 3,250 On December 31, 2020 the Company issued 117,837,384 5,330 2,329 Issuance of Series A Preferred Shares: On December 17, 2020 the Company issued 32,379,169 13,000 8,046 Quarter ended March 31,2021 Issuance of Common Shares: On January 28, 2021 the Company issued 85,900,000 5,154 On February 23, 2021 the Company issued 88,000,000 4,400 On February 24, 2021 the Company issued 82,759,286 30,000 4,758 On March 2, 2021 the Company issued 119,269,538 5,260 2,492 On March 18, 2021 the Company issued 70,000,000 3,415 84 On March 31, 2021 the Company issued 40,000,000 1926 74 Quarter Ended June 30,2021 Issuance of Common Shares On April 12, 2021 the Company issued 85,000,000 3111 49 On April 13, 2021 the Company issued 83,636,833 3,510 1508 On April 13, 2021 the Company issued 10,000 On April 13, 2021 the Company issued 32,968,042 19,000 4736 On April 15, 2021 the Company issued 146,452,000 6,340 3,179 On April 15, 2021 the Company issued 49482000 2288 680 On April 16, 2021 the Company issued 70,755,885 47,000 8,189 On April 16, 2021 the Company issued 90,311,411 4,238 17 On April 21, 2021 the Company issued 163,814,000 7655 2,264 On April 28, 2021 the Company issued 28,784,167 22,000 3,905 On May 3, 2021 the Company issued 33,012,555 1,416 729 On May 5, 2021 the Company issued 27,753,016 1,187 616 On May 18, 2021 the Company issued 33,772,000 2,026 Quarter ended September 30, 2021. Issuance of Common Shares On July 16, 2021 the Company issued 198,439,000 500 19,344 On July 22, 2021 the Company issued 200,000,000 10,000 10,000 On August 2, 2021 the Company issued 100,000,000 10,000 On September 10 , 2021 the Company issued 1,919,726 35,000 12,993 On September 30, 2021 the Company issued 70,000,000 4,200 Issuance of Series A Preferred Shares: On September 30, 2021 the Company issued 17,850,919 140,000 68,535

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13. SUBSEQUENT EVENTS On October 1, 2021 the Company issued 101,718,058 425,000 154,991 On October 1, 2021 the Company issued 5,869,589 50,000 23,369 On October 29, 2021 the Company issued 25748147 140,000 54,000 On November 4 , 2021 the Company issued 8626613 50,000 69,012 On November 24 , 2021 the Company issued 77355500 92,247 36,967 On December 10 2021 the Company issued 1,425,000 25,000 10,625

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of September 30, 2021 utilized the following inputs: Schedule of Derivative Liability Schedule of Derivative Liability Risk Free Interest Rate 1.49 % Expected Term ( 3.07 1.09 Expected Volatility 824.95 % Expected Dividends
INCOME TAXES	H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100 Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $ 0
NOTES RECEIVABLE	K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. As of September 30,2021 the Company has the following Notes Receivable Schedule of notes receivable Zander Therapeutics, Inc. $ 5,396 $5,396 owed to the Company by Zander Therapeutics, Inc. bears simple interest at 10% and is due upon the demand of the Company.
REVENUE RECOGNITION	L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.
INTEREST RECEIVABLE	M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Derivative Liability	Schedule of Derivative Liability Schedule of Derivative Liability Risk Free Interest Rate 1.49 % Expected Term ( 3.07 1.09 Expected Volatility 824.95 % Expected Dividends
Schedule of notes receivable	Schedule of notes receivable Zander Therapeutics, Inc. $ 5,396

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Notes Payable Related Party	Notes Payable Related Party Notes Payable Related Party As of September 30, 2021 David Koos $ 227 Total: $ 227
Non Related Party	Non Related Party Coventry Enterprises LLC, $ 1,500,000 Total: $ 1,500,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Deferred tax assets	Deferred tax assets Deferred tax assets Deferred tax assets: Net operating tax carry forwards $ 4,903,269 Other -0- Gross deferred tax assets 4,903,269 Valuation allowance (4,903,269 ) Net deferred tax assets $ -0-

INVESTMENT SECURITIES, RELATE_2

INVESTMENT SECURITIES, RELATED PARTY (Tables)	12 Months Ended
	Sep. 30, 2021
Investment Securities Related Party
Dividend Income	Dividend Income Dividend Income Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 74,298 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 20,274 Investment Securities 593,357 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 500,000 Accrued Expenses Related Parties 89,529 Accrued Expenses 203,037 Enterprise Value 2,826,507 Less: Total Debt ( 2,061,607 ) Portion of Enterprise Value Attributable to Shareholders 764,900 Fair Value Per Share $ 0.0167
Comprehensive Income	Comprehensive Income 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gains Net Unrealized Gain or (Loss) realized during the Year ended September 30,2021 $ 5,741 $ 7,858 $ 2,118 $ 0 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the Year ended September 30,2021 $ 13,124 $ 12,109 $ (1,104 ) $ 0

INVESTMENT SECURITIES (Tables)

INVESTMENT SECURITIES (Tables)	12 Months Ended
	Sep. 30, 2021
Disclosure Investment Securities Abstract
Investment Securities	Investment Securities 18,300 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the Year ended September 30,2021 $ 677,100 $ 198,006 $ 479,094 479,094

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Line Items]
Risk Free Interest Rate	1.49%
Expected Volatility	824.95%
Maximum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	3 years 25 days
Minimum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	1 year 1 month 2 days

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	Sep. 30, 2021USD ($)
Zander Therapeutics
Defined Benefit Plan Disclosure [Line Items]
Long-term Investments and Receivables, Net	$ 5,396

ORGANIZATION AND SUMMARY OF S_6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Accounting Policies [Abstract]
Valuation allowance	100.00%
Advertising expenses	$ 0	$ 0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative)	113 Months Ended
	Sep. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	$ 23,348,900

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)	Sep. 30, 2021USD ($)
Short-term Debt [Line Items]
Notes Payable	$ 227
David Koos
Short-term Debt [Line Items]
Notes Payable	$ 227

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1)	Sep. 30, 2021USD ($)
Short-term Debt [Line Items]
Notes Payable	$ 1,500,000
Coventry Enterprises L L C [Member]
Short-term Debt [Line Items]
Notes Payable	$ 1,500,000

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 17, 2021	Sep. 30, 2021	Sep. 30, 2020
Short-term Debt [Line Items]
Debt instrument interest rate	5.00%
Principal amount	$ 1,500,000
Original ssue discount	75,000
Transaction cost	35,000
Paymemt for fee	1,390,000
Interest amount	62,500		$ 0
Periodic payments	$ 312,500
Unamortized discount		71,048
David Koos
Short-term Debt [Line Items]
Note payable		$ 227
Debt instrument interest rate		15.00%
David Koos
Short-term Debt [Line Items]
Note payable		$ 227
Debt instrument interest rate		15.00%

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021
Short-term Debt [Line Items]
Unamortized discount	$ 71,048
Outstanding balance	9,057
Convertible Note; March 8, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	8.00%
Beneficial conversion feature	$ 42,600
Unamortized discount	0
Outstanding balance	100,000
Convertible Note; April 6, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	8.00%
Beneficial conversion feature	$ 9,900
Unamortized discount	0
Outstanding balance	50,000
Convertible Note; October 31, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Convertible Note #2; October 31, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Convertible Note #3; October 31, 2016
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Outstanding balance	50,000
Convertible Note; March 1, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	75,000
Cash issued for convertible note	$ 75,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	75,000
Converted value that exceeds the principal amount	75,000
Derivative Liability	296,052
Convertible Note; March 9, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	98,684
Convertible Note; March 13, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note: March 31, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; April 19, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	98,684
Convertible Note #2; April 19, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; May 5, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	200,000
Cash issued for convertible note	$ 200,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	200,000
Converted value that exceeds the principal amount	200,000
Derivative Liability	789,474
Convertible Note; May 10, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	394,737
Convertible Note; May 19, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; June 26, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	150,000
Cash issued for convertible note	$ 150,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	150,000
Converted value that exceeds the principal amount	150,000
Derivative Liability	592,105
Convertible Note; July 24, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	60,000
Cash issued for convertible note	$ 60,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	60,000
Converted value that exceeds the principal amount	60,000
Derivative Liability	236,842
Convertible Note; August 29, 2017
Short-term Debt [Line Items]
Unamortized discount	0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	98,684
Convertible Note; September 22, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; #2 September 22, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	394,737
Convertible Note; September 25, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; October 3, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; October 4, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	40,000
Cash issued for convertible note	$ 40,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	40,000
Converted value that exceeds the principal amount	40,000
Derivative Liability	157,894
Convertible Note; October 16, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	394,737
Convertible Note; November 01, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	98,684
Convertible Note; #2 November 1, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	1000.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	98,684
Convertible Note; December 20, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	394,737
Convertible Note #2; December 20, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	115,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	8.00%
Unamortized discount	$ 0
Outstanding balance	115,000
Converted value that exceeds the principal amount	10,964
Derivative Liability	42,169
Original Issue Discount	1,750
Convertible Note; December 06, 2017
Short-term Debt [Line Items]
Convertible note issued and outstanding	50,000
Cash issued for convertible note	$ 50,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	50,000
Converted value that exceeds the principal amount	50,000
Derivative Liability	197,368
Convertible Note; January 24, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	25,000
Cash issued for convertible note	$ 25,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	25,000
Converted value that exceeds the principal amount	25,000
Derivative Liability	98,684
Convertible Note; February 28, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	100,000
Converted value that exceeds the principal amount	100,000
Derivative Liability	394,737
Convertible Note; May 18, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	114,000
Cash issued for convertible note	$ 100,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	114,000
Converted value that exceeds the principal amount	65,149
Derivative Liability	138,125
Original Issue Discount	$ 14,000
Maturity Date	Feb. 18, 2019
Convertible Note; July 11, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	$ 11,500
Cash issued for convertible note	$ 11,500
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	11,500
Converted value that exceeds the principal amount	11,500
Derivative Liability	45,394
Convertible Note; September 30, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	350,000	$ 350,000
Cash issued for convertible note	$ 350,000
Convertible note, interest rate	10.00%	10.00%
Outstanding balance	$ 10,000
Converted value that exceeds the principal amount	10,000
Convertible Note; October 3, 2018
Short-term Debt [Line Items]
Convertible note issued and outstanding	63,000
Cash issued for convertible note	$ 60,000
Convertible note, interest rate	8.00%
Unamortized discount	$ 0
Outstanding balance	63,000
Derivative Liability	14,770
Convertible Note; July 19, 2019
Short-term Debt [Line Items]
Convertible note issued and outstanding	100,000
Cash issued for convertible note	$ 95,000
Convertible note, interest rate	8.00%
Unamortized discount	$ 0
Outstanding balance	1,000
Derivative Liability	1,766
Convertible Note #2; July 19, 2019
Short-term Debt [Line Items]
Convertible note issued and outstanding	20,331
Cash issued for convertible note	18,831
Unamortized discount	0
Outstanding balance	20,331
Derivative Liability	$ 33,157

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Sep. 30, 2021	Jun. 30, 2021
Short-term Debt [Line Items]
Notes Payable, Current	$ 9,057
Notes Payable, Related Parties, Current	227
Convertible Note; September 30, 2018
Short-term Debt [Line Items]
Convertible Notes Payable, Current	$ 350,000	$ 350,000
Debt Instrument, Interest Rate, Effective Percentage	10.00%	10.00%
Notes Payable, Current	$ 10,000
David Koos
Short-term Debt [Line Items]
Notes Payable, Related Parties, Current	227
Long-term Debt, Gross	$ 227

INCOME TAXES (Details)

INCOME TAXES (Details)	Sep. 30, 2021USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 4,903,269
Other	0
Gross deferred tax assets	4,903,269
Valuation allowance	(4,903,269)
Net deferred tax assets	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	Sep. 30, 2021USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 4,903,269
Net operating loss carry forwards	$ 23,348,900

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Sep. 30, 2021	Sep. 30, 2020
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common stock, authorized	4,800,000,000	4,800,000,000
Common stock issued	4,350,554,514	1,605,000,246
Common stock outstanding	4,350,554,514	1,605,000,246
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series AA Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued and outstanding		50,000
Preferred stock, shares outstanding	50,000	50,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued and outstanding		431,998,817
Preferred stock, shares outstanding	381,768,689	431,998,817
Series M Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued and outstanding		44,000,000
Preferred stock, shares outstanding	44,000,000	44,000,000
Series N C [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	0
Preferred stock, shares outstanding	10,000	0

INVESTMENT SECURITIES, RELATE_3

INVESTMENT SECURITIES, RELATED PARY (Details) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Prepaid Expenses	$ 48,144	$ 28
Accrued Interest Receivable	230	0
Accounts Payable	91,498	$ 110,486
Common Stock [Member] | Zander Therapeutics
Fair Value of Intellectual Property	1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	2,061,607
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167
Series M Preferred Stock [Member] | Zander Therapeutics
Fair Value of Intellectual Property	$ 1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	2,061,607
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167

INVESTMENT SECURITIES, RELATE_4

INVESTMENT SECURITIES, RELATED PARY (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020
Investment Securities, Fair Value		$ 198,006	$ 0
Common Stock [Member] | Zander Therapeutics
Investment Securities, Basis		5,741
Investment Securities, Fair Value		7,858
Investment Securities, Total Unrealized Gain		2,118
Investment Securities, net Unrealized Gain or (Loss) realized		$ 0
Series M Preferred Stock [Member] | Zander Therapeutics
Investment Securities, Basis	$ 13,124
Investment Securities, Fair Value	12,109
Investment Securities, Total Unrealized Gain	(1,104)
Investment Securities, net Unrealized Gain or (Loss) realized	$ 0

INVESTMENT SECURITIES, RELATE_5

INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) - Zander Therapeutics - USD ($)	Jun. 11, 2019	Nov. 29, 2019	Sep. 30, 2021
Number of shares issued for property dividend	470,588		470,588
Series M Preferred Stock [Member]
Number of shares issued in satisfaction of prepaid rent and accrued interest		725,000	725,000
Shares issued in satisfaction of prepaid rent and accrued interest, value		$ 13,124

INVESTMENT SECURITIES (Details

INVESTMENT SECURITIES (Details 1) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Available-for-sale Securities	$ 198,006	$ 0
Common Stock [Member] | Oncology Pharma [Member]
Investment Securities, Basis	677,100
Available-for-sale Securities	198,006
Investment Securities, Total Unrealized Gain	479,094
Series M Preferred Stock [Member] | Oncology Pharma [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ 479,094

INVESTMENT SECURITIES (Detail_2

INVESTMENT SECURITIES (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2021	Sep. 30, 2021
Unrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	13,000
Proceeds from Issuance or Sale of Equity	$ 300,000	$ 195,000
Zander Therapeutics
Defined Benefit Plan Disclosure [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		18,000

STOCK TRANSACTIONS (Details Nar

STOCK TRANSACTIONS (Details Narrative) - USD ($)	Sep. 10, 2021	Aug. 02, 2021	May 05, 2021	May 03, 2021	Apr. 13, 2021	Apr. 12, 2021	Mar. 02, 2021	Dec. 11, 2020	Sep. 30, 2021	Jul. 22, 2021	Jul. 16, 2021	May 18, 2021	Apr. 28, 2021	Apr. 21, 2021	Apr. 16, 2021	Apr. 15, 2021	Mar. 31, 2021	Mar. 18, 2021	Feb. 24, 2021	Feb. 23, 2021	Jan. 28, 2021	Dec. 31, 2020	Dec. 23, 2020	Dec. 17, 2020	Dec. 16, 2020	Nov. 26, 2020	Oct. 28, 2020
Convertible Debt [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Shares issued in satisfaction of convertible identedness	1,919,726	100,000,000	27,753,016	33,012,555	83,636,833	85,000,000	119,269,538	87,020,000	70,000,000	200,000,000	198,439,000	33,772,000	28,784,167	163,814,000	70,755,885	146,452,000	40,000,000	70,000,000	82,759,286	88,000,000	85,900,000	117,837,384	108,444,444	83,216,917	6,437,153	83,934,153	80,065,846
Value of shares issued in satisdaction of convertible debt	$ 35,000	$ 10,000	$ 1,187	$ 1,416	$ 3,510	$ 3,111	$ 5,260	$ 7,300	$ 4,200	$ 10,000	$ 500	$ 2,026	$ 22,000	$ 7,655	$ 47,000	$ 6,340	$ 1,926	$ 3,415	$ 30,000	$ 4,400	$ 5,154	$ 5,330	$ 16,000	$ 8,200	$ 429	$ 3,900	$ 3,752
Accrued Interest	$ 12,993		$ 616	$ 729	$ 1,508	$ 49	$ 2,492	$ 3,142		$ 10,000	$ 19,344		$ 3,905	$ 2,264	$ 8,189	$ 3,179	$ 74	$ 84	$ 4,758			$ 2,329	$ 3,250	$ 1,786	$ 236	$ 1,555	$ 1,452
Convertible Debt [Member] | Series A Preferred Stock [Member]
Short-term Debt [Line Items]
Shares issued in satisfaction of convertible identedness									17,850,919															32,379,169
Value of shares issued in satisdaction of convertible debt									$ 140,000															$ 13,000
Accrued Interest									$ 68,535															$ 8,046
Convertible Debt [Member] | Series N C Preferred Stock [Member]
Short-term Debt [Line Items]
Shares issued in satisfaction of convertible identedness					10,000
Convertible Debt 1 [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Shares issued in satisfaction of convertible identedness					32,968,042										90,311,411	49,482,000									88,158,923
Value of shares issued in satisdaction of convertible debt					$ 19,000										$ 4,238	$ 2,288									$ 4,030
Accrued Interest					$ 4,736										$ 17	$ 680									$ 1,700

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Convertible Debt [Member] - USD ($)	Dec. 10, 2021	Nov. 04, 2021	Oct. 02, 2021	Sep. 10, 2021	Aug. 02, 2021	May 05, 2021	May 03, 2021	Apr. 13, 2021	Apr. 12, 2021	Mar. 02, 2021	Dec. 11, 2020	Nov. 24, 2021	Oct. 29, 2021	Sep. 30, 2021	Jul. 22, 2021	Jul. 16, 2021	May 18, 2021	Apr. 28, 2021	Apr. 21, 2021	Apr. 16, 2021	Apr. 15, 2021	Mar. 31, 2021	Mar. 18, 2021	Feb. 24, 2021	Feb. 23, 2021	Jan. 28, 2021	Dec. 31, 2020	Dec. 23, 2020	Dec. 17, 2020	Dec. 16, 2020	Nov. 26, 2020	Oct. 28, 2020
Common Stock [Member]
Subsequent Event [Line Items]
Shares issued in satisfaction of convertible identedness				1,919,726	100,000,000	27,753,016	33,012,555	83,636,833	85,000,000	119,269,538	87,020,000			70,000,000	200,000,000	198,439,000	33,772,000	28,784,167	163,814,000	70,755,885	146,452,000	40,000,000	70,000,000	82,759,286	88,000,000	85,900,000	117,837,384	108,444,444	83,216,917	6,437,153	83,934,153	80,065,846
Value of shares issued in satisdaction of convertible debt				$ 35,000	$ 10,000	$ 1,187	$ 1,416	$ 3,510	$ 3,111	$ 5,260	$ 7,300			$ 4,200	$ 10,000	$ 500	$ 2,026	$ 22,000	$ 7,655	$ 47,000	$ 6,340	$ 1,926	$ 3,415	$ 30,000	$ 4,400	$ 5,154	$ 5,330	$ 16,000	$ 8,200	$ 429	$ 3,900	$ 3,752
Accrued Interest				$ 12,993		$ 616	$ 729	$ 1,508	$ 49	$ 2,492	$ 3,142				$ 10,000	$ 19,344		$ 3,905	$ 2,264	$ 8,189	$ 3,179	$ 74	$ 84	$ 4,758			$ 2,329	$ 3,250	$ 1,786	$ 236	$ 1,555	$ 1,452
Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Shares issued in satisfaction of convertible identedness														17,850,919															32,379,169
Value of shares issued in satisdaction of convertible debt														$ 140,000															$ 13,000
Accrued Interest														$ 68,535															$ 8,046
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Shares issued in satisfaction of convertible identedness		8,626,613	101,718,058									77,355,500	25,748,147
Value of shares issued in satisdaction of convertible debt		$ 50,000	$ 425,000									$ 92,247	$ 140,000
Accrued Interest		$ 69,012	$ 154,991									$ 36,967	$ 54,000
Subsequent Event [Member] | Series A Preferred Stock [Member]
Subsequent Event [Line Items]
Shares issued in satisfaction of convertible identedness	1,425,000		5,869,589
Value of shares issued in satisdaction of convertible debt	$ 25,000		$ 50,000
Accrued Interest	$ 10,625		$ 23,369